Internal Medicine, Gastroenterology and Hepatology, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.
Internal Medicine, Fondazione Policlinico Agostino Gemelli IRCCS, Rome, Italy.
Sci Rep. 2019 Oct 25;9(1):15373. doi: 10.1038/s41598-019-51867-6.
Minimal hepatic encephalopathy (MHE) is a subclinical complication of liver cirrhosis with a relevant social impact. Thus, there is urgent need to implement easy to use diagnostic tools for the early identification of affected patients. The aim of this study was to investigate cerebral blood flow, systemic hemodynamics as well as endothelial function of cirrhotic patients with MHE, and to verify their change after treatment with rifaximin. Fifty cirrhotic patients with or without MHE and an equal number of healthy controls underwent transcranial Doppler ultrasound (TCD), abdominal Doppler ultrasound (US), and measurement of flow mediated dilation (FMD). In cirrhotic patients diagnosed with MHE receiving rifaximin, the tests were repeated at the end of treatment. Middle (MCA) and posterior (PCA) cerebral artery resistive (RI) and pulsatility (PI) indices were higher in cirrhotic patients than controls, as well as renal and splenic artery RI. Conversely, FMD was reduced. MCA-RI and PI were even higher in cirrhotic patients with MHE compared to those without; a MCA-RI cut-off of 0.65 showed an accuracy of 74% in discriminating the presence of MHE, with 65% sensitivity and 76% specificity. Rifaximin treatment showed no efficacy in the modulation of cerebral vascular flow. In conclusion, cirrhotic patients with MHE have significantly increased cerebral vascular resistances that are not improved by rifaximin treatment. MCA-RI measurement has a good accuracy for the diagnosis of MHE and can be useful for the early identification of this harmful complication of liver cirrhosis.
轻微型肝性脑病(MHE)是肝硬化的一种亚临床并发症,具有相关的社会影响。因此,迫切需要使用易于使用的诊断工具来早期识别受影响的患者。本研究旨在研究伴有或不伴有 MHE 的肝硬化患者的脑血流、全身血液动力学和内皮功能,并验证利福昔明治疗后的变化。50 例肝硬化伴或不伴 MHE 的患者和 50 例健康对照者接受经颅多普勒超声(TCD)、腹部多普勒超声(US)和血流介导的扩张(FMD)测量。在诊断为 MHE 的肝硬化患者接受利福昔明治疗后,在治疗结束时重复进行这些检查。大脑中动脉(MCA)和后动脉(PCA)的阻力(RI)和搏动性(PI)指数在肝硬化患者中高于对照组,以及肾动脉和脾动脉 RI。相反,FMD 降低。与无 MHE 的肝硬化患者相比,患有 MHE 的肝硬化患者的 MCA-RI 和 PI 更高;MCA-RI 截断值为 0.65 时,区分 MHE 存在的准确性为 74%,敏感性为 65%,特异性为 76%。利福昔明治疗对脑血管流量的调节没有效果。总之,患有 MHE 的肝硬化患者的脑血管阻力显著增加,利福昔明治疗不能改善。MCA-RI 测量对 MHE 的诊断具有良好的准确性,可用于早期识别这种肝硬化的有害并发症。